These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21368869)

  • 1. Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
    Sears D; Luong P; Yuan M; Nteliopoulos G; Man YK; Melo JV; Basu S
    Cell Death Dis; 2010 Nov; 1(11):e93. PubMed ID: 21368869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
    Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
    Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S; Holtz M; Gupta M; Bhatia R
    Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
    Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
    Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
    Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
    Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
    Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
    J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
    Joha S; Nugues AL; Hétuin D; Berthon C; Dezitter X; Dauphin V; Mahon FX; Roche-Lestienne C; Preudhomme C; Quesnel B; Idziorek T
    Oncogene; 2012 Mar; 31(11):1419-30. PubMed ID: 21804606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
    Wu J; Meng F; Lu H; Kong L; Bornmann W; Peng Z; Talpaz M; Donato NJ
    Blood; 2008 Apr; 111(7):3821-9. PubMed ID: 18235045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
    Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
    Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
    Coluccia AM; Vacca A; Duñach M; Mologni L; Redaelli S; Bustos VH; Benati D; Pinna LA; Gambacorti-Passerini C
    EMBO J; 2007 Mar; 26(5):1456-66. PubMed ID: 17318191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
    Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
    Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
    Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.
    Zhang QY; Mao JH; Liu P; Huang QH; Lu J; Xie YY; Weng L; Zhang Y; Chen Q; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3378-83. PubMed ID: 19208803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.